Liver mass risk factors

Jump to: navigation, search

Liver Mass Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differential Diagnosis

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

Evaluation of Liver Mass

Staging

History and Symptoms

Physical Examination

Laboratory Studies

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Case Studies

Case #1

Liver mass risk factors On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Liver mass risk factors

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Liver mass risk factors

CDC on Liver mass risk factors

Liver mass risk factors in the news

Blogs on Liver mass risk factors

Directions to Hospitals Treating bone or soft tissue mass

Risk calculators and risk factors for Liver mass risk factors

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Dildar Hussain, MBBS [2]; Aditya Ganti M.B.B.S. [3]

Overview

Common risk factors in the development of liver masses include chronic hepatitis B infection, chronic hepatitis C infection, cirrhosis, inherited metabolic diseases and aflaoxins.

Risk Factors

Common Risk Factors

Common risk factors that may increase the risk of developing liver mass include:[1][2][3][4][5][6][7][8][9][10]

Less Common Risk Factors

Less common risk factors that may increase the risk of developing liver mass include:[11][12][13][14]

References

  1. National Cancer Institute. Physician Data Query Database 2015.http://www.cancer.gov/types/liver/hp/adult-liver-treatment-pdq
  2. Trichopoulos D, Bamia C, Lagiou P, Fedirko V, Trepo E, Jenab M, Pischon T, Nöthlings U, Overved K, Tjønneland A, Outzen M, Clavel-Chapelon F, Kaaks R, Lukanova A, Boeing H, Aleksandrova K, Benetou V, Zylis D, Palli D, Pala V, Panico S, Tumino R, Sacerdote C, Bueno-De-Mesquita HB, Van Kranen HJ, Peeters PH, Lund E, Quirós JR, González CA, Sanchez Perez MJ, Navarro C, Dorronsoro M, Barricarte A, Lindkvist B, Regnér S, Werner M, Hallmans G, Khaw KT, Wareham N, Key T, Romieu I, Chuang SC, Murphy N, Boffetta P, Trichopoulou A, Riboli E (2011). "Hepatocellular carcinoma risk factors and disease burden in a European cohort: a nested case-control study". J. Natl. Cancer Inst. 103 (22): 1686–95. doi:10.1093/jnci/djr395. PMC 3216968. PMID 22021666.
  3. Cecil, Russell L., James B. Wyngaarden, and Lloyd H. Smith. Textbook of . Philadelphia: Saunders, 1988. Print.
  4. "Redirecting".
  5. CHEDID, Marcio F.; KRUEL, Cleber R. P.; PINTO, Marcelo A.; GREZZANA-FILHO, Tomaz J. M.; LEIPNITZ, Ian; KRUEL, Cleber D. P.; SCAFFARO, Leandro A.; CHEDID, Aljamir D. (2017). "HEPATOCELLULAR CARCINOMA: DIAGNOSIS AND OPERATIVE MANAGEMENT". ABCD. Arquivos Brasileiros de Cirurgia Digestiva (São Paulo). 30 (4): 272–278. doi:10.1590/0102-6720201700040011. ISSN 2317-6326.
  6. Fujiwara N, Friedman SL, Goossens N, Hoshida Y (2017). "Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine". J. Hepatol. doi:10.1016/j.jhep.2017.09.016. PMID 28989095.
  7. Trad, Dorra; Bibani, Norsaf; Sabbah, Meriam; Elloumi, Hela; Gargouri, Dalila; Ouakaa, Asma; Kharrat, Jamel (2017). "Known, new and emerging risk factors of hepatocellular carcinoma (review)". La Presse Médicale. 46 (11): 1000–1007. doi:10.1016/j.lpm.2017.09.025. ISSN 0755-4982.
  8. Budny A, Kozłowski P, Kamińska M, Jankiewicz M, Kolak A, Budny B, Budny W, Niemunis-Sawicka J, Szczypiór G, Kurniawka B, Burdan F (2017). "[Epidemiology and risk factors of hepatocellular carcinoma]". Pol. Merkur. Lekarski (in Polish). 43 (255): 133–139. PMID 28987047.
  9. Parkin, Donald Maxwell (2006). "The global health burden of infection-associated cancers in the year 2002". International Journal of Cancer. 118 (12): 3030–3044. doi:10.1002/ijc.21731. ISSN 0020-7136.
  10. Shi, J; Zhu, L; Liu, S; Xie, W-f (2005). "A meta-analysis of case–control studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma in China". British Journal of Cancer. 92 (3): 607–612. doi:10.1038/sj.bjc.6602333. ISSN 0007-0920.
  11. Trad, Dorra; Bibani, Norsaf; Sabbah, Meriam; Elloumi, Hela; Gargouri, Dalila; Ouakaa, Asma; Kharrat, Jamel (2017). "Known, new and emerging risk factors of hepatocellular carcinoma (review)". La Presse Médicale. 46 (11): 1000–1007. doi:10.1016/j.lpm.2017.09.025. ISSN 0755-4982.
  12. Clavière C, Bronowicki JP, Hudziak H, Bigard MA, Gaucher P (1998). "[Role of sex steroids and their receptors in the pathophysiology of hepatocellular carcinoma]". Gastroenterol. Clin. Biol. (in French). 22 (1): 73–86. PMID 9762169.
  13. "Studies of Cancer in Humans - Tobacco Smoke and Involuntary Smoking - NCBI Bookshelf".
  14. "Tobacco smoke and involuntary smoking". IARC Monogr Eval Carcinog Risks Hum. 83: 1–1438. 2004. PMC 4781536. PMID 15285078.

Linked-in.jpg